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Combined DNA, toxicological and 
heavy metal analyses provides 
an auditing toolkit to improve 
pharmacovigilance of traditional 
Chinese medicine (TCM)
Megan L. Coghlan1, Garth Maker2,3, Elly Crighton2,3, James Haile1, Dáithí C. Murray1, 
Nicole E. White1, Roger W. Byard4,5, Matthew I. Bellgard6, Ian Mullaney2,3, 
Robert Trengove2, Richard J.N. Allcock7,8, Christine Nash5, Claire Hoban4, Kevin Jarrett9, 
Ross Edwards9, Ian F. Musgrave4 & Michael Bunce1
Globally, there has been an increase in the use of herbal remedies including traditional Chinese 
medicine (TCM). There is a perception that products are natural, safe and effectively regulated, 
however, regulatory agencies are hampered by a lack of a toolkit to audit ingredient lists, adulterants 
and constituent active compounds. Here, for the first time, a multidisciplinary approach to assessing 
the molecular content of 26 TCMs is described. Next generation DNA sequencing is combined with 
toxicological and heavy metal screening by separation techniques and mass spectrometry (MS) to 
provide a comprehensive audit. Genetic analysis revealed that 50% of samples contained DNA of 
undeclared plant or animal taxa, including an endangered species of Panthera (snow leopard). In 50% 
of the TCMs, an undeclared pharmaceutical agent was detected including warfarin, dexamethasone, 
diclofenac, cyproheptadine and paracetamol. Mass spectrometry revealed heavy metals including 
arsenic, lead and cadmium, one with a level of arsenic >10 times the acceptable limit. The study 
showed 92% of the TCMs examined were found to have some form of contamination and/or 
substitution. This study demonstrates that a combination of molecular methodologies can provide an 
effective means by which to audit complementary and alternative medicines.
The use of complementary and alternative medicine is becoming increasingly popular worldwide1,2. It 
is generally believed that since herbal remedies are of natural origin, they are therefore safe, that there 
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are legal safeguards in place to ensure quality, and that they have fewer side effects than conventional 
medicines3,4. Recently, questions surrounding the safety and legality of complementary and alternative 
medicines (CAMs), such as traditional Chinese medicine (TCM), have prompted increased scrutiny. 
Several studies have shown that there is a lack of accuracy in labelling of some TCM, with undeclared 
animals and plants, including toxic and endangered species identified by DNA analyses5–7. It has also 
been shown that some TCM contain unsafe levels of heavy metals8, or can be adulterated with pharma-
ceutical drugs9–11. However, the negative health impacts of herbal medicines are difficult to quantify, as 
reporting rates for adverse reactions are low and the use of herbal medicines is often not reported to 
healthcare professionals9.
Regulatory bodies such as the US Food and Drug Administration (FDA), the UK Medicines and 
Healthcare Products Regulatory Agency (MHRA) and the Therapeutic Goods Administration (TGA) in 
Australia are entrusted with regulating herbal products, including TCMs, prepared or sold within their 
borders. Medicines that are thought to contain low-risk ingredients often only require the manufacturer 
to declare what is contained within their products, a form of regulation referred to as ‘light-touch’12. To 
assess the effectiveness of this regulatory system, an accurate post-market auditing strategy of herbal 
medicines is required, a sentiment endorsed in World Health Organisation strategy reports13.
The field of complementary and alternative medicine polarises the public, health care professionals, 
regulators and researchers, but efficacy arguments aside, most would agree that herbal CAMs should be 
safe, unadulterated, legal and honestly labelled. In this study, we set out to evaluate the content of 26 
legally purchased TCMs, using a combination of molecular screening methods. This study is the first 
of its kind, and aims to provide much-needed pharmacovigilance strategies for pre- and post-market 
auditing of herbal CAMs.
Results
Genetic analyses. The plant and animal composition of the 26 TCMs were genetically analysed using 
both 454 (Roche) GS Junior and Ion Torrent PGM NGS platforms (Table  1). Multiple mtDNA and 
plastid genes were targeted for species identification in this study. Of the 26 TCM samples collected, 22 
(84%) had sufficient DNA (determined by qPCR) to progress to amplicon sequencing. The raw data that 
passed quality filter totalled 593,100 reads, averaging at approximately 32,000 reads per sample across 
the markers.
The taxonomic assignments from the mtDNA and plastid DNA data are listed in Table 1 and discussed 
below. As the taxonomic assignments of every plant contained in the TCM were too numerous to list 
here, a sub-set of the plant data is shown in Table 1. The plant family and genera in the table are primarily 
those that should be flagged on the grounds of toxicity, legality or relate to discussions of the openly 
acknowledged ingredients. Finally, in Table 1 we have carefully examined the declared plant and animal 
ingredients (where available) of both TGA listed and unlisted TCMs to evaluate their accuracy. A TCM 
was deemed to have not correctly declared its ingredients when DNA originating from a ‘concerning’ or 
trade restricted plant/animal was detected.
Toxicological data. Each of the 26 TCM samples was extensively tested for potential adulterants 
using LC-MS analysis. Each of the compounds was carefully assessed relative to known standards, and a 
limit of quantitation and limit of detection was constructed for each compound. A total of 18 different 
toxicological compounds were detected in 13 TCMs listed in Table 2. In positive samples, the number 
of adulterants and/or undeclared substances varied from one (TCMs 8, 13, 22, and 26) to six detected 
in the TGA-listed TCM2.
The amounts of the adulterants and/or undeclared substances detected were variable between samples 
as indicated in Table 2. The mere presence of some of these compounds contravenes both TGA regula-
tions and Australian law. In Table 2, the dosage instructions were used with each medicine (see Table S3) 
and the calculated nominal dosage of the pharmacological adulterant under this regime was compared 
to doses used in clinical practice.
Heavy metal data. Twenty-five out of the 26 TCM samples were screened for heavy metal con-
tamination using SF-ICP-MS. The aqueous state of TCM17 prevented it from being analysed using 
the above method. Three potentially toxic metals to humans, arsenic, cadmium and lead were the 
focus of this analysis, many of which are present in quantities that exceed recommended daily intakes 
(see Table 3 for calculations). Of the 25 TCMs analysed, 20 contained at least one of these metals (arse-
nic, lead or cadmium) in varying quantities (Table  3). Eleven samples contained all three toxic metals 
with amounts detected ranging from just above the acceptable TGA limit (for a 60 kg person taking 
the recommended dose) up to and beyond 10 times the TGA limit for medicines (Table 3). As with the 
toxicological data described above, the exposure estimates to the heavy metals were calculated based on 
the dosage instructions (Table S3) on the medicine packaging and then referenced to the TGA guidelines 
for heavy metal concentrations in medicines. The raw SF-ICP-MS results in parts per million (PPM) for 
all heavy metals screened in this study can be found in Table S4.
Figure 1 provides a summary of all TCMs that were deemed to be either compliant or non-compliant 
based on the three screening methods combined. Out of the 26 medicines analysed, two of these (8%) 
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Family Genus
AUST L TCMs Non Listed TCMs







































Acanthaceae Andrographis ✓ ✓ ✓
Amaranthaceae Amaranthus ✓
Apiaceae Bupleurum ✓ ✓
Apocynaceae Apocynum ✓ ✓ ✓ ✓
Asparagaceae Anemarrhena ✓ ✓
Asteraceae ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓




Fabaceae Astragalus ✓ ✓ ✓ ✓ ✓ ✓ ✓
Glycyrrhiza ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Dipsacaceae Dipsacus ✓ ✓
Ephedraceae Ephedra ✓
Lamiaceae Mentha ✓ ✓ ✓ ✓
Perilla ✓ ✓ ✓ ✓
Scutellaria ✓
Lardizabalaceae Sargentodoxa ✓
Loranthaceae Taxillus ✓ ✓
Moraceae Morus ✓ ✓ ✓ ✓ ✓ ✓
Nelumbonaceae Nelumbo ✓ ✓ ✓
Pedaliaceae ✓
Polygonaceae Oxyria ✓ ✓
Paeoniaceae Paeonia ✓ ✓ ✓ ✓ ✓
Salicaceae Salix ✓










Canidae Canis ✓ ✓ ✓ ✓
Felidae Panthera ✓
Felis ✓ ✓
Muridae Rattus ✓ ✓ ✓
Rhacophoridae Polypedates ✓
Viperidae Deinagkistrodon ✓
Table 1.  Selected plant and animal families and genera detected in 18 traditional Chinese medicine 
(TCM) samples by mitochondrial and plastid DNA analysis.
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were not found to contain undeclared substances and are therefore displayed as being ‘compliant’ with 
the regulatory body standards.
Discussion
This study describes the first detailed combined DNA, toxicological, and heavy metal audit of herbal 
medicine employing both next generation DNA sequencing technologies and mass spectrometry-based 
detection. The focus of this study was on 26 TCMs purchased “over the counter” within Australia, how-
ever many of these medicines are also for sale on the international market. Of the 26 TCM samples, 12 
were classified as “Listed” by the TGA, with the remainder having no listing meaning that they should 
not have been commercially available. In Australia, and elsewhere, herbal products such as TCMs are 
regarded as low-risk and therefore undergo less stringent regulation. In some jurisdictions TCMs are 
simply classified as ‘dietary supplements’. Regardless of how they are categorised, the regulatory frame-
work relies heavily, or exclusively on the assumption that manufacturers are making accurate declarations 
regarding the composition of their products. In the case of the TCMs studied here, it is clear that such 
declarations are not always correct; i.e. there were major discrepancies between what was declared, either 
to the regulatory agency, or to the consumer in the form of an ingredient list.
Coghlan et al. (2012) had demonstrated that a DNA-based NGS approach is a powerful way to scrutinise 
TCM for plant and animal components5. The potential for DNA barcoding to be used for improving phar-
macovigilance of herbal medicines has also been well highlighted in a recent review14. In the current study, 
toxicological and heavy metal analyses complement the genetic data so that DNA composition, potential 
adulterants and contaminating heavy metals can be assessed in combination (summarised in Fig.  1). 
Our analysis of the 26 TCMs identified a complex list of materials that ranged from harmless contami-
nants, to illegal or potentially dangerous adulterants and/or heavy metals.
The TCM that most clearly breaches international law is TCM8 (used to treat “arthritis” and “pain”) 
where two mtDNA signatures (differing by one polymorphism) were recovered that provided a 100% match 
to species within the genus Panthera. This sample contained DNA from snow leopard (Panthera uncia),  
and possibly tiger (Panthera tigris), both of which are listed within the Convention on the International 
Trade in Endangered Species of flora and fauna (CITES) Appendix I. Appendix I affords the highest 
level of trade restriction. This result was checked using independent DNA isolations from TCM8 and 
Compound Identified
AUST L TCMs Non Listed TCMs
2 7 8 11 22 23 1 13 14 18 19 21 26
Analgesic
Paracetamol* + + + + 
Salicyclic acid# + + + + + + + 





Dexamethasone* + + + + + + 
Betamethasone* + 




Brucine # + + + 
Strychnine # + + + 
PDE inhibitor Sildenafil* + + 
Stimulant
Caffeine # + + + + + 
Pseudo/ephedrine# + + + + + + + + + + + 
Methylephedrine # + + + + 
Theophylline # + 
Antibiotics Amoxicillin* + + 
Table 2.  Adulterants/undeclared compounds detected in the traditional Chinese medicine (TCM) 
samples tested in this study. Of the 26 TCMs screened using toxicological/metabolomic techniques, those 
appearing in the table below were found to contain pharmaceutical and/or naturally occurring compounds, 
none of which were on ingredients lists. + Trace amount detected. + + Amount detected is physiologically 
relevant, above trace levels but below clinically used levels. + + + Clinically significant amount detected. 
*Synthetically derived compound. #Could be naturally occurring or synthetically derived.
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2 + + + + + + 
3 + + + 
6 + + 
7 + + + + + + 
8 + + + 
9 + + 
11 + + + + + + 
12 + + + + + + 
15 + + + + 
22 + 
23 + + + + 
Non Listed TCMs
 1 + + + + + 
 4 + + + + + + + + 
 5 + + + + 
 13 + + + + + + + + 
 16 + + + 
 19 + + + + + + + 
 24 + + + + 
 25 + + + + + + + 
 26 + + + + + + + 
Table 3.  Toxic heavy metals detected in the traditional Chinese medicine (TCM) samples tested in this 
study. Of the 25 TCMs screened using SF-ICP-MS, those appearing in the table below were found to contain 
the toxic metals arsenic, lead or cadmium in varying quantities. + At or less than two times the TGA limit 
for medicines (based on 60 kg person; 1.2 μ g/daily dose arsenic, 2.2 μ g/daily dose lead, 0.22 μ g/daily  
dose cadmium). ++ Greater than two times the TGA limit for medicines. +++ Greater than 10 times the 























Figure 1. Summary of traditional Chinese medicines (TCMs) tested in this study that contained toxic 
metals, undeclared or illegal contents as determined by DNA, toxicological, and heavy metal screening 
methods. Each TCM tested is represented in the diagram as a tablet; blue shading on tablets indicate AUST 
L listed medicines, red shading are not-listed with the TGA regulatory body. TCMs deemed non-compliant 
for DNA (green), toxicology (pink) and heavy metals (yellow) or a combination thereof, are represented 
within the Venn diagram. ‘Non compliance’ is defined as containing an illegal or undeclared species, 
undeclared pharmaceutical, or heavy metal in quantities beyond the allowable daily dosage limit. Two TCM’s 
were classified as ‘undetected’ using the testing methods described.
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sequencing them on 454, Ion Torrent and Illumina NGS platforms. Finally, the presence of snow leopard 
was confirmed by successful amplification of P. uncia using a species-specific PCR assay15. TCMs have 
previously been shown to contain trade-restricted species listed within the appendices of CITES16–18. The 
presence of Panthera DNA in a TGA ‘Listed’ medicine is therefore of great concern. On the basis of this 
identification alone, TCM8 is illegal to import or sell and an incorrect declaration has been made to the 
regulatory agency.
Material from taxa such as Panthera (TCM8), pit viper (TCM 11) and frogs (TCM 19) are likely 
to have been deliberately added as a primary ingredient. However the reproducible detection of DNA 
from ‘domestic’ animals (cow, goat, sheep, dog, cat, and rat, see Table 1) in a given sample could mean 
that these are either also undeclared ingredients, or alternatively are inadvertent contaminants during 
manufacture. As none of these products have declared any animal ingredients, this may indicate major 
deficiencies in manufacturing standards.
The presence of DNA assigning to plant species such as Asarum (TCM1) is of concern due to the clear 
carcinogenic risks associated with aristolochic acid5,19,20. Likewise, the undeclared presence of DNA from 
the Ephedra genus in this same TCM makes the product illegal to sell in most jurisdictions. Four TCM 
samples contained DNA that could be assigned to the genus Apocynum, which has very restricted use 
and is on the registry of poisonous (FDA), restricted or prohibited plants (MHRA and TGA). Apocynum 
species are known to contain cardiac glycosides (e.g. cymarin), which are cardiotoxins that can cause 
arrhythmias.
Up to 24% of TCM preparations have been previously reported to be adulterated with pharmaceuticals11. 
The current toxicological data showed between 19% and 50% of the preparations were adulterated 
depending on whether compounds such as ephedrine and salicylic acid were naturally derived or were 
synthetic adulterants.
From a toxicological perspective, TCM2 (described as “reducing hay fever” and “nasal secretions”) 
was perhaps the most concerning as a ‘cocktail’ of six undeclared compounds were detected: ephedrine 
(1097 μ g/g), chlorpheniramine (1025 μ g/g), salicylic acid (25.2 μ g/g), amoxicillin (18 μ g/g), methylephed-
rine (10 μ g/g) and small quantities of warfarin (4 μ g/g). The interactions of the analgesic, antibiotic, 
stimulant and antihistamine drugs in this single TCM preparation are difficult to predict. This may be 
even more significant if the preparation is used by children or pregnant women.
In some instances there was a clear correlation between the genetic and toxicological analyses. The 
ephedrine detected in TCM1 correlates with the detection of Ephedra DNA. In other instances Ephedra 
DNA could not be detected when ephedrine was present, and this may be because a synthetic adulter-
ant was added to the preparation or, alternatively, the DNA was too highly degraded for detection. In 
another example, there was no obvious genetic sequence that could account for the brucine (3405 μ g/g), 
and strychnine (1509 μ g/g) detected in TCM1, although species outside of the Strychnos genus may also 
generate these alkaloids.
A potentially recurring theme was that the adulterant compounds found in the TCMs were often 
‘tailored’ to deliver the purported therapeutic outcome21. For example, TCM18 which aimed at enhanc-
ing weight gain with appetite stimulation contained both dexamethasone (6034 μ g/g) and cyprohepta-
dine (20333 μ g/g), the latter of which is a known appetite enhancer22. The dose of cyproheptadine in a 
single capsule was 8mg, while the typical therapeutic dose is 2–4 mg. TCM18 also contained DNA from 
the genus Morus (mulberry, Table 1), which some practitioners claim, plays a role in digestive function. 
Such findings are not only of concern to the consumer, but also flag the need for detailed auditing of 
herbal preparations prior to evaluation in clinical trials. It is possible, indeed likely, that given the scope 
and dose of the adulterants (listed in Table 2) that many TCM’s would perform better than placebo in 
randomised trials.
Of the 16 heavy metals screened for in this study, particular attention is paid to three toxic metals; 
arsenic, cadmium and lead. All three metals are highly toxic to humans if exposure is high, potentially 
causing severe adverse health effects or death, with arsenic and cadmium also having documented 
carcinogenicity23,24. TCM19 stands out as one of the most highly toxic medicines upon heavy metal 
analysis, with the levels of arsenic detected well over 10 times the daily limit for medicines (Table  3). 
Coupled with this finding is also the detection of a synthetic drug, diclofenac, and multiple undeclared 
animal DNA signatures found within this sample. TCM1 is again highlighted with levels of lead 
and cadmium detected that were over two times the TGA limit for medicines, as well as multiple 
pharmaceutical adulterants found, and potentially toxic plant material. Both TCM1 and TCM19 are 
non-listed medicines that again should not have been available for sale within Australia.
This study presents genetic, toxicological, and heavy metal data that should be of serious concern 
to regulatory agencies, medical professionals and the public who choose to adopt TCM as a treatment 
option. Of the 26 TCMs investigated, all but two can be classified as non-compliant on the grounds 
of DNA, toxicology and heavy metals, or a combination thereof (Fig.  1). In total, 92% were deemed 
non-compliant with some medicines posing a serious health risk. The multi-tiered approach outlined in 
this study provides a much-needed auditing toolkit that should swiftly form the basis of best-practice 
pharmacovigilance across the CAM sector.
www.nature.com/scientificreports/
7Scientific RepoRts | 5:17475 | DOI: 10.1038/srep17475
Methods
Sample collection. Twenty-six pre-packaged TCM samples were purchased from retail stores and 
TCM practitioners in South Australia, many of which are also available for purchase internationally 
online. Sample types included; capsules, tablets, and herbal teas and one liquid sample. A list of the 
samples (with branding anonymised), including whether the product is categorised as a listed medicine 
by the regulatory body (the TGA), can be found in the supplementary information (Table S1).
DNA extraction and quantification. DNA characterisation of the TCM samples followed Coghlan, 
Haile et al. (2012)5. Briefly, small amounts of each sample (between 45–300 mg), together with extraction 
controls, were digested overnight, on a shaking heat block at 55 °C, in 0.7–1.5 mL of tissue digest buffer 
consisting of; proteinase K powder (Amresco, OH, USA), 20 mM Tris (Sigma, MO, USA), 2.5 mM EDTA 
(Invitrogen, CA, USA), 5 mM CaCl2 (Sigma), 20 mM dithiothreitol solution (Thermo Fisher Scientific, 
MA, USA), 1% sodium dodecyl sulfate (Invitrogen), and Milli-Q water. 200 μ L of digest was mixed with 
1 mL of Qiagen (CA, USA) PB buffer and purified and washed on a silica spin column and finally eluted 
with 50 μ L of EB buffer (Qiagen, CA, USA).
The extracted DNA was quantified by amplifying plant and mammal DNA gene regions: trnL g/h, 
rbcL, and 16S rRNA25–27, (primer information can be found in Supplementary Table S2) using an ABI 
StepONE qPCR (Applied Biosystems, USA) platform. All PCRs were carried out in a 25 μ L volume includ-
ing: 2 mM MgCl2 (Applied Biosystems, USA), 1 × Taq polymerase buffer (Applied Biosystems, USA), 
0.4 μ M dNTPs (Astral Scientific, Australia), 0.1 mg bovine serum albumin (Fisher Biotec, Australia) 
when required to counteract inhibition, 0.4 μ M of each primer, 0.2 μ L of AmpliTaq Gold DNA polymer-
ase (Applied Biosystems, USA) and SYBR-Green dye. The qPCR conditions were: 50 cycles of 95 °C for 
30 seconds, annealing at primer specific temperature (Supplementary Information, Table S2) for 30 sec-
onds, 72 °C for 30 seconds. The qPCR was carried out for each sample at three dilution points (undiluted, 
1/10 and 1/100) to gauge template copy number and identify if PCR inhibitors were present.
Amplicon generation. Fusion primers with unique 6–8 bp multiplex identifier (MID) tags were 
designed for the plant and mammal primer sets used for qPCR above. Amplicon sequencing was carried 
out on both a 454 (Roche, USA) GS Junior instrument as described previously5, and using a Personal 
Genome Machine (PGM) (Life Technologies, CA, USA) according to manufacturer’s protocols. All 
amplicons were generated in triplicate and assigned unique forward and reverse multiplex identifier 
(MID) tags to ensure that any contamination from previously generated amplicons could be excluded 
post sequencing. Primer sequences used in this study are provided in the supplementary information 
(Table S2).
Bioinformatic analysis. The sequencing output files were retrieved, filtered, and processed using 
Geneious (v6.1)28. Reads were deemed to have passed filter when they had exact matches for prim-
ers and MID tag sequences at both amplicon ends. A non-redundant sequence set (removal of exact 
matches) for each sample was generated using USEARCH29. These files were then analysed for chimeras 
in USEARH using the UCHIME de novo method30 and removed, along with singletons and imported 
into YABI31 where a BLASTn search was conducted against the National Centre for Biotechnology 
Information (NCBI) GenBank NR database32,33. The resultant BLAST files were then imported into the 
program MEtaGenome ANalyzer (MEGAN v4.69.4)34 for taxonomic scrutiny. The amplicon sequences 
were assigned using the following lowest common ancestor parameters: min score of 65, top percent of 
5, and min support of 1. Each taxonomic assignment was critically evaluated using available databases 
and is a conservative estimate of families, genera and species. Processed amplicon data described herein 
is available from Dryad Digital Repository: http://dx.doi.org/10.5061/dryad.ps04c.
Toxicological analysis. TCM samples were crushed in a clean mortar and pestle, and 5 mg of each 
was extracted with methanol containing 0.05 mg/mL diphenhydramine (internal standard), for 1 min-
ute at 6500 rpm in a Precellys tissue lyser (Bertin Technologies, France). Extracts were centrifuged for 
5 minutes at 1.3 × 104 × g and diluted 1:10 with LC-MS water for analysis. The final internal standard 
concentration was 5 ng/mL.
Samples were analysed using a Varian 212 HPLC system coupled to a 325-MS triple quadrupole mass 
spectrometer, using electrospray ionisation (Agilent Technologies, USA). The column was a Restek Ultra 
Aqueous C18 (100 mm × 2·1 mm × 3 μ m) (Restek Technologies, USA), with mobile phase A being LC-MS 
water and mobile phase B being 0.1% formic acid in acetonitrile. Analysis was repeated with mobile 
phase B as methanol to expand coverage of possible adulterants. The nebuliser gas (air) was set at 70 psi, 
the vortex gas at 30 psi and 300°C and the drying gas at 25 psi and 200°C (both N2). Mobile phase was 
held at 95% A for 2 minutes before ramping to 100% B by 9 minutes, held for 5 minutes, back to 95% A 
by 15 minutes, held for 5 minutes.
Eighteen likely adulterants were selected and, to establish optimal MS/MS conditions, standards of 
each were infused into the MS at 1 μ g/mL. A minimum of two transitions per compound were selected 
and the dwell time for each transition was 0.025 s for a total scan time of 0.85 s, with the detector set at 
1100 V. Standard curves were generated for each compound over the range 0.1 to 100 ng/ml. Data was 
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analysed using Varian MS Workstation v6.9.3 (Agilent Technologies), with peak areas normalised to the 
internal standard.
Heavy metal analysis. TCM samples were leached in concentrated nitric acid (HNO3) to screen for 
bioavailable toxic metals. The “acid leachable” method does not determine total metal concentrations 
but is representative of metals released from the TCM samples in-vitro. For reporting purposes, the 
concentrations determined by the method should be considered an underestimate of the total metal 
concentrations contained within TCM. Powdered TCM samples (~0.3 g) were added to acid-cleaned 
polypropylene vials containing 5 mL of ultrapure nitric acid (~70% concentration, double distilled) and 
leached for 24 hours at room temperature. Following acid leaching samples were made up to 10 mL with 
ultrapure water (> 18 mΩ ), filtered (acid-cleaned 0.2 μ m PTFE filter membrane) and diluted 1: 75 with 
3% ultrapure HNO3.
Sixteen heavy metals were determined under ultra-trace clean conditions using a sector-field induc-
tively coupled plasma mass spectrometer (SF-ICP-MS, Thermo Fisher Scientific ELEMENT XR) housed 
in the Curtin University ultra-clean TRACE facility. Samples were mixed with an internal standard 
(Indium) and introduced to the SF-ICP-MS using an auto-sampler (Elemental Scientific Inc, Seafast II) 
enclosed in a metal free hood. Instrumental and full procedural blanks (3% HNO3), replicates and quality 
control standards (high Purity Standards, CWW-TM-A) were determined at regular intervals through-
out the analysis. Internal standard normalised ions intensities were quantified using “matrix matched” 
external standards prepared by serial dilution from commercial primary standards. The results were 
blank subtracted and corrected for dilution. TCMs were deemed non-compliant if the concentration of 
the heavy metals lead, cadmium and arsenic were above the threshold daily intake levels set by the TGA 
for a 60kg person.
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